Trials / Not Yet Recruiting
Not Yet RecruitingNCT07348653
A Study of MG2512 Injection in Participants With Advanced Solid Tumors
A Phase I Study of Safety, Tolerability, Pharmacokinetics and Efficacy of MG2512 Injection in Participants With Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 116 (estimated)
- Sponsor
- Shanghai Mabgen Biopharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and efficacy of MG2512 injection in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MG2512 Injection | MG2512 injection. |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2026-01-16
- Last updated
- 2026-01-21
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07348653. Inclusion in this directory is not an endorsement.